A Randomised, Double Blind, Cross-over Trial Comparing the Safety and Efficacy of Insulin Degludec and Insulin Glargine, With or Without OADs in Subjects With Type 2 Diabetes (SWITCH 2)

Trial Profile

A Randomised, Double Blind, Cross-over Trial Comparing the Safety and Efficacy of Insulin Degludec and Insulin Glargine, With or Without OADs in Subjects With Type 2 Diabetes (SWITCH 2)

Completed
Phase of Trial: Phase III

Latest Information Update: 12 Aug 2017

At a glance

  • Drugs Insulin degludec (Primary) ; Insulin glargine
  • Indications Type 2 diabetes mellitus
  • Focus Adverse reactions; Registrational
  • Acronyms BEGIN: SWITCH 2; SWITCH 2
  • Sponsors Novo Nordisk
  • Most Recent Events

    • 04 Aug 2017 Puerto Rico was also a planned location for this trial.
    • 13 Jun 2017 A budget impact analysis based on evidence from SWITCH 2 trial results presented at the 77th Annual Scientific Sessions of the American Diabetes Association
    • 13 Jun 2017 Results of a post-hoc subgroup analysis of Hispanic patients presented at the 77th Annual Scientific Sessions of the American Diabetes Association
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top